Geneva, Switzerland, April 19, 2024 – Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 – 23, 2024 at the Congress Center in Basel, Switzerland. Addex to Present at the Swiss Biotech Day 2024
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira. Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
Die heimliche Revolution der Krebsdiagnostik? Bluttests zur Krebsfrüherkennung könnten die Medizin revolutionieren. Die Idee: Mit einer einfachen Blutabnahme verschiedene Krebsarten frühzeitig und präzise erkennen. Dies würde Leben retten und die Heilungschancen verbessern, da eine Krebsdiagnose im Frühstadium oft die besten Aussichten auf Heilung bietet. Verschiedene Ansätze im Rennen Forscher verfolgen verschiedene Ansätze, um Krebs im Blut zu finden. Eine Möglichkeit ist die Suche nach zirkulierender Tumor-DNA (ctDNA). Krebszellen geben DNA ins Blut ab, die von gesunder DNA unterschieden werden kann. Andere Tests suchen nach Proteinen, Metaboliten oder Exosomen, die von Krebszellen freigesetzt werden. Vielversprechende Ergebnisse, aber noch offene Fragen Erste Studien zeigen vielversprechende Ergebnisse. So konnte der Galleri-Bluttest in einer Studie verschiedene Krebsarten mit hoher Sensitivität und Spezifität erkennen. Allerdings gibt es noch offene Fragen. So ist die Sensitivität der Tests noch nicht hoch genug, um alle Krebsfälle zu erfassen.…
The English national football team is cooperating with the Central Clinic Bad Berka during the European Football Championship. Team doctor Dr. Mark Williams visited the clinic to see the diagnostic and therapeutic options for the players and the accompanying team. The cooperation is particularly characterized by the 24-hour availability of state-of-the-art diagnostics, such as MRI and CT, as well as the outstanding expertise of the medical and nursing staff. "We are delighted about the interest and the trust. Even though we all hope that the European Football Championship will proceed without injuries or illnesses. We are happy to be competent supporters for the athletes and all other team companions, although everyone hopes that we will remain the 'bench players' in the tournament," explains Managing Director Mario Schulter. The Central Clinic Bad Berka, part of the RHÖN-KLINIKUM AG group, is one of Thuringia's major clinics with its 21 specialist clinics and departments and its over 120-year history. Around... are treated here annually.
Is a new chapter in the observation of the microcosm possibly opening? Researchers at the University of Tokyo have developed an improved form of mid-infrared microscopy that makes it possible to see the structures within living bacteria with unprecedented clarity. Researchers are surprised The new method, published in the journal Nature Photonics, achieves a [...] New dimensions of visibility: Mid-infrared microscopy better than ever before
Shenzhen, China (ots/PRNewswire) – At the Huawei Analyst Summit 2024, Steven Zhao, Vice President of Huawei's Data Communication Product Line, delivered a keynote speech titled "Accelerating Network Transformation Towards All Intelligence." Mr. Zhao highlighted how Huawei has introduced AI technologies to enhance network functions at the scenario, process, and system levels […] Huawei introduces AI technologies to accelerate network transformation for all-intelligence in the Net5.5G era
Shenzhen, China (ots/PRNewswire) – During the 21st Huawei Analyst Summit, the forum “Building F5.5G All-Optical Target Network, and Ushering in 10 Gbps UBB Intelligent Era“ was held, where industry stakeholders discussed how F5.5G optical technologies can be used to build home and industrial intelligence. Also at this forum, Bob Chen, President of the […] All-Optical F5.5G Premium Computing Network for Ubiquitous Intelligence
MONT-SAINT-GUIBERT, Belgium (ots/PRNewswire) – Leveraging patients’ personality traits to pioneer a new era of clinical research Cognivia, an innovative AI company dedicated to reshaping pharmaceutical and biotechnology clinical research through cutting-edge AI-ML algorithms, proudly announces a significant investment milestone. Vesalius Biocapital IV, SFPIM (Société Fédérale de Participations et d“Investissement) and […] Cognivia secures strategic financing of €15.5 million to support drug development with AI-ML solutions
South Korea’s biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection. „The fundamental way to deal with Dengue fever is taking the antiviral drug, which is effective on all four serotypes of the Dengue virus, in the early stage of virus infection,“ CEO Oh said. „To win emergency use authorization (EUA), we are planning basket clinical trials in such regions as Mid/South America and Southeast Asia.“ After the COVID-19 pandemic is tamed, a mounting number of people are diagnosed with Dengue fever, a viral infection that spreads through mosquitoes. The number of Dengue patients in 2024 amounts to 3.58 million in the Americas, about three times more than 2023, while those stand at about 8,200 in Thailand and 18,000 in Malaysia. Dengue deaths have been 758 in Brazil this year. The death…
Proteine in Zellen präzise zu beobachten ist für viele Forschungszweige extrem wichtig, war bisher jedoch eine große technische Hürde – vor allem in lebenden Zellen, denn die dafür nötige fluoreszente Markierung musste an jedes Protein einzeln angebracht werden. Der Forschungsgruppe um Stefan Kubicek am CeMM ist es nun gelungen, diese Hürde aus dem Weg zu räumen: Mit einem Verfahren, dass sie „vpCells“ getauft haben, lassen sich viele Proteine gleichzeitig mit fünf verschiedenen Fluoreszenzfarben markieren. Die Studie wurde im Fachjournal Nature Cell Biology (DOI: 10.1038/s41556-024-01407-w) veröfffentlicht, und die Bilder sind öffentlich zugänglich auf vpcells.cemm.at. Die von Stefan Kubiceks Gruppe vorgestellte neue Methode „visual proteomics Cells“ (abgekürzt vpCells) erlaubt es dagegen, Proteine so mit Fluoreszenz zu markieren, dass ihre endogenen Regulationsmechanismen unverändert bleiben. Anstatt ein Protein nach dem anderen zu markieren, können damit viele Proteine gleichzeitig in einem sogenannten Multiplex-Ansatz mit einem…
